Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:46 AM
Ignite Modification Date:
2025-12-25 @ 4:46 AM
NCT ID:
NCT01077518
Eligibility Criteria:
Inclusion Criteria:
* Indolent lymphoma including Grades 1-3a follicular, small lymphocytic, lymphoplasmacytic, and marginal zone lymphoma; Stages III-IV, or bulky disease, Stage II. Tumor verified CD20+ and CT imaging done at screening verifying disease
* Indolent B-cell NHL that remains stable or unresponsive during or within 6 months of treatment with rituximab or a rituximab-containing regimen
* Indolent lymphoma including grades 1-3a follicular, small lymphocytic, lymphoplasmacytic, and marginal zone lymphoma; stages III-IV, or bulky disease stage II (i.e. as any single mass \> 5 cm in any direction)
* ECOG Performance Status of 0, 1, or 2
* Life expectancy of at least 6 months
* 18 years or older
* Signed, written informed consent
Exclusion Criteria:
* Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma
* Previous allogeneic stem cell transplant
* Previous autologous stem cell transplant, fludarabine therapy, or radioimmunotherapy in the past 12 months
* Previous external beam radiation therapy to the pelvis. Previous external beam radiation therapy for bony disease to the cranium, mediastinum, and axilla, or to two or to more than 3 vertebral bodies
* High dose steroids greater to or equal to 60 mg prednisone/day (or equivalent) within 3 months of randomization. No more than 10 mg prednisone (or equivalent) daily at the time of randomization
* Prior bendamustine treatment within 1 year of randomization not resulting in a CR or PR for at least 6 months
* Treatment with anti-CD20 monoclonal antibody within 3 months of randomization
* Known CNS involvement of indolent lymphoma
* Other past or current malignancy. Subjects free of malignancy for at least 5 years or have history of definitively treated non-melanoma skin cancer, or successfully treated in situ carcinoma, are eligible
* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment
* Clinically significant cardiac disease
* History of significant cerebrovascular disease or event with significant symptoms
* Positive serology for Hepatitis B
* Current active liver or biliary disease (except Gibber's syndrome or asymptomatic gallstones, liver metastases, or otherwise stable chronic liver disease)
* Known HIV positive
* Abnormal/inadequate blood values, liver and kidney function
* Current participation in other clinical study
* Inability to comply with the protocol activities
* Lactating or pregnant women or female patients of child-bearing potential (or male patients with such partners) not willing to use adequate contraception
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01077518
Study Brief:
Protocol Section:
NCT01077518